natgillin/translations-raw huggingface dataset:
De findes i blistermultipakninger med 60 eller 60 x 1 (2 æsker med 30 eller 30 x 1) filmovertrukne tabletter og i plastflasker (der indeholder et tørremiddel, som ikke må spises) med 60 filmovertrukne tabletter. 
They are available in blister multipacks of 60 or 60x1 (2 cartons of 30 or 30x1) film-coated tablets and in plastic bottles (containing a desiccant, which should not be eaten) of 60 film-coated tablets.
Hvis samtidig administration af delamanid og ritonavir anses for nødvendig, anbefales derfor meget hyppig EKG-monitorering under hele behandlingen med delamanid (se pkt. 
Therefore, if coadministration of delamanid with lopinavir/ritonavir is considered necessary, very frequent ECG monitoring throughout the full delamanid treatment period is recommended (see section 4.5 and refer to the delamanid SmPC).
Pædiatrisk poulation 
Paediatric populations
Ved samtidig administration med phenytoin, må en øgning af Lopinavir/Ritonavir Mylan-dosis overvejes. 
When co-administered with phenytoin, an increase of Lopinavir/Ritonavir Mylan dosage may be envisaged.
Cerebrovaskulært attak, kramper, dysgeusi, agusi, tremor 
Uncommon Cerebrovascular accident, convulsion, dysgeusia, ageusia, tremor
Saquinavir 1000 mg to gange daglig 
Saquinavir 1000 mg BID
Ketoconazol, itraconazol: Serumkoncentrationerne kan stige på grund af lopinavir/ritonavirs hæmning af CYP3A. 
Ketoconazole, Itraconazole: Serum concentrations may be increased due to CYP3A inhibition by lopinavir/ritonavir.
Samtidig administration af colchicin er kontraindiceret til patienter med nedsat nyre- og/eller leverfunktion (se pkt. 
Concomitant administration with colchicine is contraindicated in patients with renal and/or hepatic impairment (see sections 4.3 and 4.5).
Derfor kan lopinavir/ritonavir tabletter tages med eller uden mad. 
Therefore, lopinavir/ritonavir tablets may be taken with or without food.
Der bør udvises forsigtighed og nedsat dosis bør overvejes, når Lopinavir/Ritonavir Mylan administreres sammen med rosuvastatin (se pkt. 
Caution should be exercised and reduced doses should be considered when Lopinavir/Ritonavir Mylan is co-administered with rosuvastatin (see section 4.4).
Der er rapporteret om Cushings syndrom hos patienter, som fik ritonavir og inhaleret eller intranasalt fluticasonpropionat; dette kan også forekomme med andre kortikosteroider, som metaboliseres via CYP3A, f.eks. budesonid (se punkt 4.4 og 4.5). 
Cushing's syndrome has been reported in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate; this could also occur with other corticosteroids metabolised via the P450 3A pathway e.g. budesonide (see section 4.4 and 4.5).
Multipakning: 60 (2 æsker med 30) filmovertrukne tabletter Multipakning: 60x1 (2 æsker med 30x1) filmovertrukne tabletter 
Multipack: 60 (2 cartons of 30) Film-coated tablets Multipack: 60x1 (2 cartons of 30x1) Film-coated tablets
Bivirkninger fra kliniske studier og erfaring post-marketing fra voksne og pædiatriske patienter: Nedenstående hændelser er blevet identificeret som bivirkninger. 
Adverse reactions from clinical trials and post-marketing experience in adult and paediatric patients:
Rivaroxaban anbefales ikke til patienter i behandling med Lopinavir/Ritonavir Mylan (se pkt. 
The use of rivaroxaban is not recommended in patients receiving concomitant treatment with Lopinavir/Ritonavir Mylan (see section 4.4).
Flergangsdosering med 400/100 mg lopinavir/ritonavir to gange dagligt i 2 uger og uden begrænsning af fødeindtagelse forårsager en gennemsnitlig  SD lopinavir maksimal plasmakoncentration (Cmax) på 12,3  45,4 g/ml, der fremkommer cirka 4 timer efter administration. 
Multiple dosing with 400/100 mg lopinavir/ritonavir twice daily for 2 weeks and without meal restriction produced a mean ± SD lopinavir peak plasma concentration (Cmax) of 12.3 ± 5.4 μg/ml, occurring approximately 4 hours after administration.
Samtidig brug af sildenafil ordineret til behandling af pulmonal arteriel hypertension og lopinavir/ritonavir er kontraindiceret (se pkt. 
Concomitant use of sildenafil prescribed for the treatment of pulmonary arterial hypertension with lopinavir/ritonavir is contraindicated (see section 4.3).
En dosisjustering af Lopinavir/Ritonavir Mylan 400 mg/400 mg (dvs. 
A dose adjustment of Lopinavir/Ritonavir Mylan 400 mg/400 mg (i.e.
Cmax Cfør dosis μg /ml 
Cpredose μg /mL
Koncentrationerne kan være nedsat på grund af CYP3A-induktion af dexamethason. 
Concentrations may be decreased due to CYP3A induction by dexamethasone.
 1,2 til < 1,4 
≥ 1.2 to < 1.4
Den gennemsnitlige EC50 for lopinavir mod 5 forskellige hiv-1-laboratoriestammer var 19 nM i fravær af humant serum. 
In the absence of human serum, the mean IC50 of lopinavir against five different HIV-1 laboratory strains was 19 nM.
Lopinavir/Ritonavir Mylan-tabletter indeholder lopinavir og ritonavir, der begge hæmmer P450 isoform CYP3A in vitro. 
Lopinavir/Ritonavir Mylan tablets contain lopinavir and ritonavir, both of which are inhibitors of the P450 isoform CYP3A in vitro.
AUC: ↑ 11,86 gange Cmax: ↑ 6,31 gange C24: ↑ 20,70 gange 
AUC: ↑ 11.86-fold Cmax: ↑ 6.31-fold C24: ↑ 20.70-fold
calciumantagonister (f.eks. felodipin, nifedipin, nicardipin); 
− calcium channel antagonists (e.g. felodipine, nifedipine, nicardipine);
Disse stigninger i plasmakoncentrationer af lægemidler, der anvendes samtidig med lopinavir/ritonavir, kan øge eller forlænge deres terapeutiske virkninger og bivirkninger (se pkt. 
These increases of plasma concentrations of co-administered medicinal products could increase or prolong their therapeutic effect and adverse events (see sections 4.3 and
Multipakning: 120 (4 æsker med 30) filmovertrukne tabletter Multipakning: 120x1 (4 æsker med 30x1) filmovertrukne tabletter Multipakning: 360 (12 æsker med 30) filmovertrukne tabletter 
Multipack: 120 (4 cartons of 30) Film-coated tablets Multipack: 120x1 (4 cartons of 30x1) Film-coated tablets Multipack: 360 (12 cartons of 30) Film-coated tablets
Det kan forårsage et fald i plasmakoncentrationer og dermed et potentielt fald i effekt af de lægemidler, der tages sammen med lopinavir/ritonavir. 
This may result in lowered plasma concentrations and potential decrease of efficacy of co-administered medicinal products.
Middelstigning i CD4+ T-celletal (celler/mm3) fra baseline 
Mean increase from baseline in CD4+ T-cell count (cells/mm3)
Kombination af lopinavir/ritonavir med atorvastatin anbefales ikke. 
The combination of lopinavir/ritonavir with atorvastatin is not recommended.
Lopinavir/ritonavir-tabletter kan tages sammen med eller uden mad. 
Lopinavir/ritonavir tablets can be taken with or without food.
Cmax: ↑ 55% 
Cmin: ↑ 51%
Administration sammen med quetiapin er kontraindiceret (se pkt. 
The concomitant administration with quetiapine is contraindicated (see section 4.5).
AUC: ↑ 6,10 gange Cmax: ↑ 4,76 gange Ctrough: ↑ 12,33 gange 
AUC: ↑ 6.10-fold Cmax: ↑ 4.76-fold Ctrough: ↑ 12.33-fold
INFORMATION I BRAILLESKRIFT Lopinavir/Ritonavir Mylan 100 mg/25 mg 
INFORMATION IN BRAILLE Lopinavir/Ritonavir Mylan 100 mg/25 mg
 0,8 til < 1,2 
≥ 0.8 to < 1.2
Alopeci, kapillarit, vaskulit 
Uncommon Alopecia, capillaritis, vasculitis Not known
Tipranavir/ritonavir (500/100 mg to gange daglig) 
Tipranavir/ritonavir (500/100 mg BID)
- Multipakning med 60 eller 60 x 1 (2 æsker med 30 eller 30 x 1) filmovertrukne tabletter. 
- Multipacks containing 60 or 60x1 (2 cartons of 30 or 30x1) film-coated tablets.
Den rapporterede tid til reaktionen indtræder, er dog mere variabel, og reaktionen kan forekomme flere måneder efter påbegyndelse af behandlingen (se pkt. 
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and can occur many months after initiation of treatment (see section 4.4).
Hvis du eller dit barn har glemt at tage Lopinavir/Ritonavir Mylan 
If you or your child forget to take Lopinavir/Ritonavir Mylan
INFORMATION I BRAILLESKRIFT Lopinavir/Ritonavir Mylan 200 mg/50 mg 
INFORMATION IN BRAILLE Lopinavir/Ritonavir Mylan 200 mg/50 mg
Naturlægemidler, som indeholder perikon (Hypericum perforatum). 
− products that contain St John's wort (Hypericum perforatum).
Lopinavir/Ritonavir Mylan indeholder natrium 
Lopinavir/Ritonavir Mylan contains sodium
Phenytoin-niveauerne bør overvåges ved samtidig administration med Lopinavir/Ritonavir Mylan. 
Phenytoin levels should be monitored when co-administering with Lopinavir/Ritonavir Mylan.
Hvis du eller dit barn holder op med at tage Lopinavir/Ritonavir Mylan 
If you or your child stop taking Lopinavir/Ritonavir Mylan
Samtidig administration af Lopinavir/Ritonavir Mylan og sekalealkaloider er kontraindiceret, da det kan føre til akut sekalealkaloider-toksicitet inklusive vasospasmer og iskæmi (se pkt. 
Concomitant administration of Lopinavir/Ritonavir Mylan and ergot alkaloids are contraindicated as it may lead to acute ergot toxicity, including vasospasm and ischaemia (see section
30 filmovertrukne tabletter 
30 Film-coated tablets
Samtidig administration af ibrutinib og Lopinavir/Ritonavir Mylan bør undgås. 
Co administration of ibrutinib and Lopinavir/Ritonavir Mylan should be avoided.
Lopinavir/Ritonavir Mylan-tabletterne indeholder lopinavir og ritonavir, der begge hæmmer P450isoformen CYP3A. 
Lopinavir/Ritonavir Mylan tablets contain lopinavir and ritonavir, both of which are inhibitors of the P450 isoform CYP3A.
100 patienter blev oprindeligt behandlet med lopinavir/ritonavir i studiet (herunder 51 patienter, der fik 400/100 mg to gange dagligt og 49 patienter på enten 200/100 mg to gange dagligt eller 400/200 to gange daglig). 
51 patients receiving 400/100 mg twice daily and 49 patients at either 200/100 mg twice daily or 400/200 mg twice daily).
(25/150/100 mg en gang dagligt + 400 mg to gange dagligt) 
(25/150/100 mg QD + 400 mg BID)
Kombinationen af Lopinavir/Ritonavir Mylan med atorvastatin anbefales ikke. 
The combination of Lopinavir/Ritonavir Mylan with atorvastatin is not recommended.
AUC: ↑ 13-gange Parenteral midazolam: 
AUC: ↑ 13-fold Parenteral Midazolam: AUC: ↑ 4-fold
Lopinavir/Ritonavir Mylan må ikke indgives en gang dagligt i kombination med carbamazepin og phenobarbital. 
Lopinavir/Ritonavir Mylan must not be administered once daily in combination with carbamazepine and phenobarbital.
Samtidig administration af lopinavir/ritonavir og af rifampicin kan ikke anbefales. 
Co-administration of lopinavir/ritonavir with rifampicin is not recommended.
Almindelig Pankreatit1, opkastning, gastroøsofageal reflukssygdom, gastroenterit og colitis, mavesmerter øvre og nedre), abdominal distension, dyspepsi, hæmorider flatulens 
Pancreatitis1, vomiting, gastrooesophageal reflux disease, gastroenteritis and colitis, abdominal pain (upper and lower), abdominal distension, dyspepsia, haemorrhoids, flatulence Uncommon Gastrointestinal haemorrhage including gastrointestinal ulcer, duodenitis, gastritis and rectal haemorrhage, stomatitis and oral ulcers, faecal incontinence, constipation, dry mouth
Den gennemsnitlige EC50 for lopinavir mod hiv-1IIIB i MT4 celler var 17 nM og 102 nM ved henholdsvis fravær eller tilstedeværelse af 50 % humant serum. 
In the absence and presence of 50% human serum, the mean IC50 of lopinavir against HIV-1IIIB in MT4 cells was 17 nM and 102 nM, respectively.
Midler mod arthritis urica Colchicin enkelt dosis 
Anti-gout agents Colchicine single dose
Aterosklerose såsom myokardieinfarkt 1, atrioventrikulært blok, trikuspidalklapinsufficiens Vaskulære sygdomme Almindelig Hypertension Ikke almindelig 
Uncommon Atherosclerosis such as myocardial infarction, atrioventricular block, tricuspid valve incompetence
Lopinavir/ritonavir kan anvendes af børn fra 2 år, unge og voksne, der er smittet med hiv, som er den virus, der forårsager aids. 
Lopinavir/ritonavir Mylan is not a cure for HIV infection or AIDS - Lopinavir/ritonavir is used by children 2 years of age or older, adolescents and adults who are infected with HIV, the virus which causes AIDS.
 0,5 til < 0,8 
≥ 0.5 to < 0.8
I tabel 6 ses de farmakokinetiske data fra hiv-1-inficerede gravide kvinder, som fik lopinavir/ritonavirtabletter 400/100 mg to gange dagligt (se pkt. 
The pharmacokinetic data from HIV-1 infected pregnant women receiving lopinavir/ritonavir tablets 400/100 mg twice daily are presented in Table 6 (see section 4.2).
Samtidig administration af elbasvir/grazoprevir med Lopinavir/Ritonavir Mylan er kontraindiceret (se pkt. 
Concomitant administration of elbasvir/grazoprevir with Lopinavir/Ritonavir Mylan is contraindicated (see section 4.3).
AUC: ↑ 2,71 gange Cmax: ↑ 1,87 gange C24: ↑ 3,58 gange 
AUC: ↑ 2.71-fold Cmax: ↑ 1.87-fold C24: ↑ 3.58-fold
60 filmovertrukne tabletter 
60 Film-coated tablets
Den gennemsnitlige EC50 for lopinavir mod flere kliniske hiv-1-isolater var 6.5 nM i fravær af humant serum. 
In the absence of human serum, the mean IC50 of lopinavir was 6.5 nM against several HIV-1 clinical isolates.
120 filmovertrukne tabletter 
120 Film-coated tablets
Hud og subkutane væv Almindelig Udslæt inklusive makulopapuløst udslæt, dermatit/udslæt inklusive eksem og seboreisk dermatit, nattesved, pruritus 
Rash including maculopapular rash, dermatitis/rash including eczema and seborrheic dermatitis, night sweats, pruritus
Fluticasonpropionat, 50 g intranasalt 4 gange daglig: Plasmakoncentrationer ↑ Kortisolniveauer ↓ 86% 
Plasma concentrations ↑ Cortisol levels ↓ 86%
talcum, polysorbat 80. 
Silica, colloidal anhydrous Polysorbate 80
hiv-RNA < 400 kopier/ml hiv-RNA < 50 kopier/ml 
HIV RNA < 400 copies/ml
Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. 
Check with your doctor or pharmacist if you are not sure how you should take your medicine.
Sikkerheden af lopinavir/ritonavir er blevet undersøgt hos over 2.600 patienter i kliniske afprøvninger fase II/IV. 
The safety of lopinavir/ritonavir has been investigated in over 2600 patients in Phase II-IV clinical trials, of which over 700 have received a dose of 800/200 mg (6 capsules or 4 tablets) once daily.
AUC: ↑ 7,2 gange Cmax: ↑ 4,7 gange Cmin: ↑ 14,4 gange 
AUC: ↑ 7.2-fold Cmax: ↑ 4.7-fold Cmin: ↑ 14.4-fold
Dyrestudier indikerer ikke, at lopinavir/ritonavir har effekt på fertiliteten. 
Animal studies have shown no effects on fertility.
I nogle studier blev lopinavir/ritonavir anvendt i kombination med efavirenz og nevirapin sammen med nukleosid revers transkriptasehæmmere (NRTIs). 
Along with nucleoside reverse transcriptase inhibitors (NRTIs), in some studies, lopinavir/ritonavir was used in combination with efavirenz or nevirapine.
Non-nukleosid revers transkriptasehæmmere (NNRTIs) Efavirenz, 600 mg en gang dagligt 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Efavirenz, 600 mg QD Lopinavir: AUC: ↓ 20%
Hvis behandling med Lopinavir/Ritonavir Mylan er nødvendig, anbefales det, at colchicin-dosis nedsættes eller behandling med colchicin afbrydes hos patienter med normal nyre- eller leverfunktion. 
A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with Lopinavir/Ritonavir Mylan is required.
hiv-RNA < 400 kopier/ml* hiv-RNA < 50 kopier/ml*† 
HIV RNA < 400 copies/ml*
Brug af anden medicin sammen med Lopinavir/Ritonavir Mylan 
Other medicines and Lopinavir/Ritonavir Mylan
Rilpivirin (Lopinavir/ritonavir kapsel 400/100 mg to gange daglig) 
Rilpivirine (Lopinavir/ritonavir capsule 400/100 mg BID)
Gennemsnitlig CD4+ Tcelletal ved baseline var 838 celler/mm3 og gennemsnitlig plasma hiv-1-RNA ved baseline var 4,7 log10 kopier/ml. 
Mean baseline CD4+ T-cell count was 838 cells/mm3 and mean baseline plasma HIV-1 RNA was 4.7 log10 copies/ml.
Antidepressiva og anxiolytika Trazodon enkeltdosis 
Antidepressants and Anxiolytics
Behandling af pulmonal arteriel hypertension: Samtidig administration af Lopinavir/Ritonavir Mylan og sildenafil er kontraindiceret (se 
For the treatment of pulmonary arterial hypertension: Coadministration of Lopinavir/Ritonavir Mylan with sildenafil is contraindicated (see section 4.3).
Gennemsnitlig baseline CD4+ T-celletal var 259 celler/mm3 (interval: 2 til 949 celler/ mm3) og gennemsnitlig baseline plasma hiv-1-RNA var 4,9 log10 kopier/ml (interval: 2,6 til 6,8 log10 kopier/ml). 
Mean baseline CD4+ T-cell count was 259 cells/mm3 (range: 2 to 949 cells/mm3) and mean baseline plasma HIV-1 RNA was 4.9 log10 copies/ml (range: 2.6 to 6.8 log10 copies/ml).
Samtidig administration af Lopinavir/Ritonavir Mylan og ranolazin er kontraindiceret (se pkt. 
The concomitant administration of Lopinavir/Ritonavir Mylan and ranolazine is contraindicated (see section 4.3).
Median CD4+ T-celletal ved baseline var 216 celler/mm3 (interval: 20 til 775 celler/mm3) og middel plasma-HIV-1 RNA ved baseline var 5,0 log10 kopier/ml (interval: 1,7 til 7,0 log10 kopier/ml). 
Mean baseline CD4+ T-cell count was 216 cells/mm3 (range: 20 to 775 cells/mm3) and mean baseline plasma HIV-1 RNA was 5.0 log10 copies/ml (range: 1.7 to 7.0 log10 copies/ml).
Sådan du tage Lopinavir/Ritonavir Mylan 
How to take Lopinavir/Ritonavir Mylan
- Multipakning med 120, 120 x 1 (4 æsker med 30 eller 30 x 1) eller 360 (12 æsker med 30) 
- Multipacks containing 120, 120x1 (4 cartons of 30 or 30x1) or 360 (12 cartons of 30) film-coated tablets.
Cytostatika Afatinib 
Monitor for ADRs related to afatinib
Spædbørn og små børns evne til at synke hele tabletter skal vurderes, inden ordination af lopinavir/ritonavir 100/25 mg tabletter. 
Before prescribing lopinavir/ritonavir 100/25 mg tablets, infants and young children should be assessed for the ability to swallow intact tablets.
Lopinavir/Ritonavir Mylan 200 mg/50 mg filmovertrukne tabletter OPA/Al/PVC-aluminium-blisterpakning. 
Lopinavir/Ritonavir Mylan 200 mg/50 mg film-coated tablets OPA/Al/PVC-aluminium blister pack.
Hvis samtidig administration af delamanid og Lopinavir/Ritonavir Mylan er nødvendigt, anbefales meget hyppig EKG-monitorering i hele behandlingsperioden med delamanid, da DM-6705 er forbundet med risiko for forlænget QTc (se pkt. 
Due to the risk of QTc prolongation associated with DM-6705, if coadministration of delamanid with Lopinavir/Ritonavir Mylan is considered necessary, very frequent ECG monitoring throughout the full delamanid treatment period is recommended (see section 4.4 and refer to the delamanid SmPC).
Lopinavir/Ritonavir Mylan 100 mg/25 mg filmovertrukne tabletter OPA/Al/PVC-aluminium-blisterpakning. 
Lopinavir/Ritonavir Mylan 100 mg/25 mg film-coated tablets OPA/Al/PVC-aluminium blister pack.
Der skal udvises forsigtighed ved administration af afatinib med Lopinavir/Ritonavir Mylan. 
Caution should be exercised in administering afatinib with Lopinavir/Ritonavir Mylan.
MÆRKNING, DER SKAL ANFØRES PÅ DEN INDRE EMBALLAGE FLASKE (ETIKET) 
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING BOTTLE (LABEL)
HMG-CoAreduktase-hæmmere 
HMG Co-A Reductase Inhibitors
Samtidig administration af Lopinavir/Ritonavir Mylan og boceprevir anbefales ikke. 
It is not recommended to coadminister Lopinavir/Ritonavir Mylan and boceprevir.
Etravirin (Lopinavir/ritonavir tablet 400/100 mg to gange daglig) 
Etravirine (Lopinavir/ritonavir tablet 400/100 mg BID)
Lopinavir/Ritonavir Mylan 200 mg/50 mg filmovertrukne tabletter Hver filmovertrukket tablet indeholder 200 mg lopinavir formuleret sammen med 50 mg ritonavir, der virker som en farmakokinetisk forstærker. 
Lopinavir/Ritonavir Mylan 200 mg/50 mg film-coated tablets Each film-coated tablet contains 200 mg of lopinavir co-formulated with 50 mg of ritonavir as a pharmacokinetic enhancer.
Det skal du vide, før du eller dit barn begynder at tage Lopinavir/Ritonavir Mylan 
What you need to know before you or your child takes Lopinavir/Ritonavir Mylan
Samtidig administration af Lopinavir/Ritonavir Mylan og fusidinsyre er kontraindiceret ved dermatologiske infektioner på grund af den forøgede risiko for bivirkninger, især rhabdomyolyse (se pkt. 
Concomitant administration of Lopinavir/Ritonavir Mylan with fusidic acid is contra-indicated in dermatological indications due to the increased risk of adverse events related to fusidic acid, notably rhabdomyolysis (see section 4.3).
Der skal udvises forsigtighed ved administration af ceritinib med Lopinavir/Ritonavir Mylan. 
Caution should be exercised in administering ceritinib with Lopinavir/Ritonavir Mylan.
Lopinavir/Ritonavir Mylan 100 mg/25 mg filmovertrukne tabletter. 
Lopinavir/Ritonavir Mylan 100 mg/25 mg film-coated tablets.
Mediant CD4+ T-celletal ved baseline var 254 celler/mm3 (interval: 4 til 952 celler/mm3) og median plasma-HIV-1 RNA ved baseline var 4,3 log10 kopier/ml (interval: 1,7 til 6,6 log10 kopier/ml). 
Mean baseline CD4+ T-cell count was 254 cells/mm3 (range: 4 to 952 cells/mm3) and mean baseline plasma HIV-1 RNA was 4.3 log10 copies/ml (range: 1.7 to 6.6 log10 copies/ml).
Deraf udledes at lopinavir/ritonavir s antivirale effekt skyldes lopinavir. 
Therefore, the antiviral activity of lopinavir/ritonavir is due to lopinavir.
Samtidig administration af Lopinavir/Ritonavir Mylan og tadalafil anbefales ikke. 
Coadministration of Lopinavir/Ritonavir Mylan with tadalafil is not recommended.
Sildenafil brugt til at behandle potensproblemer kan tages efter lægens vejledning (se punktet Brug af anden medicin sammen med Lopinavir/Ritonavir Mylan). 
Sildenafil used to treat erectile dysfunction may be taken under doctor's supervision (see Other medicines and Lopinavir/ritonavir Mylan section);
Lopinavir/Ritonavir Mylan 200 mg/50 mg filmovertrukne tabletter. 
Lopinavir/Ritonavir Mylan 200 mg/50 mg film-coated tablets.
Reducer ibrutinib-dosis til 140 mg, og monitorer patienten tæt for toksicitet, hvis 
If the benefit is considered to outweigh the risk and Lopinavir/Ritonavir Mylan must be used, reduce the ibrutinib dose to 140 mg and monitor patient closely for toxicity.
Fusidinsyre brugt til behandling langvarige infektioner i knogler og led kan tages med rådgivning fra lægen (se Brug af anden medicin sammen med Lopinavir/Ritonavir Mylan); (brugt til behandling af urinsyregigt), hvis du har problemer med nyre- og/eller lever (se punktet Brug af anden medicin sammen med Lopinavir/Ritonavir Mylan); elbasvir/grazoprevir (bruges til at behandle kronisk hepatitis C-virus [HCV]); ombitasvir/paritaprevir/ritonavir med eller uden dasabuvir bruges til at behandle kronisk hepatitis C-virus [HCV]); avanafil eller vardenafil (brugt til behandling af potensproblemer); sildenafil ved brug til behandling af unormalt højt blodtryk i lungernes blodkar pulmonal arteriel hypertension). 
− colchicine (used to treat gout) if you have kidney and/or liver problems (see the section on Other medicines and Lopinavir/Ritonavir); elbasvir/grazoprevir (used to treat chronic hepatitis C virus [HCV]); ombitasvir/paritaprevir/ritonavir with or without dasabuvir (used to treat chronic hepatitis C virus [HCV]);
AUC: ↑ 5,9-gange Cmax: ↑ 4,7-gange På grund af lopinavir/ritonavirs hæmning af CYP3A. 
AUC: ↑ 5.9-fold Cmax: ↑ 4.7-fold Due to CYP3A inhibition by lopinavir/ritonavir.
Lopinavir/Ritonavir Mylan 100 mg/25 mg filmovertrukne tabletter Hver filmovertrukket tablet indeholder 100 mg lopinavir formuleret sammen med 25 mg ritonavir, der virker som en farmakokinetisk forstærker. 
Lopinavir/Ritonavir Mylan 100 mg/25 mg film-coated tablets Each film-coated tablet contains 100 mg of lopinavir co-formulated with 25 mg of ritonavir as a pharmacokinetic enhancer.
Det kan være nødvendigt med justering af Lopinavir/Ritonavir Mylan-dosis. 
The dose of Lopinavir/Ritonavir Mylan may need adjusting.
ANVENDELSESMÅDE OG ADMINISTRATIONSVEJ(E) Læs indlægssedlen inden brug. 
METHOD AND ROUTE(s) OF ADMINISTRATION Read the package leaflet before use.
ANVENDELSESMÅDE OG administrationsVEJ(E) Læs indlægssedlen inden brug. 
METHOD AND ROUTE(S) OF ADMINISTRATION Read the package leaflet before use.
Samtidig administration af Lopinavir/Ritonavir Mylan og astemizol og terfenadin er kontraindiceret, da risikoen for alvorlige arytmier forårsaget af disse lægemidler kan øges (se pkt. 
Concomitant administration of Lopinavir/Ritonavir Mylan and astemizole and terfenadine is contraindicated as it may increase the risk of serious arrhythmias from these agents (see section 4.3).